10 completed, 4 recruiting, 3 terminated, 1 active not recruiting. 8 Phase 3, 5 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Completed 5, Terminated 2, Withdrawn 1 |
| Phase 2 | 5 | Completed 2, Recruiting 2, Active not recruiting 1 |
| Phase 1 | 2 | Completed 1, Terminated 1 |
Follow Acute Leukemia French Association: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| OBServatory of Compassionate Use of IVOsidenib in France for Patients With Acute Myeloid Leukemia AML, Adult | Recruiting | French Innovative Leukemia Organisation | 250 | 2024-07-31 | 2025-11-26 | |
| Results From a French Temporary Utilization Authorization of First-line Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Chemotherapy (IC), Treated With Venetoclax Azacitidine AML, Adult | Unknown | French Innovative Leukemia Organisation | 230 | 2024-07-04 | 2024-07-23 | |
| Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia AzaCITIDine Oral Tablet, Xospata - AML, Adult, Refractory AML | Phase 2 | Recruiting | French Innovative Leukemia Organisation | 33 | 2024-01-13 | 2025-03-24 |
| A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD and/or FLT3-TKD Relapse/Refractory (R/R) AML Gemtuzumab ozogamicine - Cytarabine - Gilteritinib - AML, Leukaemia (Acute Myeloid) | Phase 2 | Active not recruiting | Centre Antoine Lacassagne | 19 | 2023-06-03 | 2026-01-05 |
| CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics Cytarabine and Idarubicin, CPX-315 - Acute Myeloid Leukemia | Phase 2 | Recruiting | Centre Hospitalier Universitaire de Nice | 248 | 2023-05-03 | 2026-03-27 |
| Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML) Acute Myeloid Leukemia (AML) | Recruiting | Acute Leukemia French Association | 5000 | 2022-04-14 | 2025-10-03 | |
| Evaluation of CPX-351 Monotherapy in Acute Myeloid Leukemia Secondary to Myeloproliferative Neoplasm CPX-351 - Acute Myeloid Leukemia, Myeloproliferative Syndrome | Phase 2 | Completed | French Innovative Leukemia Organisation | 42 | 2022-03-23 | 2024-10-29 |
| Multicenter Retrospective Observatory of Patients With Acute Myeloid Leukemia to Core Binding Factor NOT PROVIDED - Acute Myeloblastic Leukemia Core Binding Factor | Completed | Acute Leukemia French Association | 400 | 2021-09-22 | 2025-10-02 | |
| A Non-interventional Ambispective Real-world Cohort of rEfractory and reLapsed (R/R) FLT3 Mutated Acute MyEloid Leukemia (AML) Patients Treated With Gilteritinib in FrANCE Refractory AML, Relapsed Adult AML | Completed | French Innovative Leukemia Organisation | 177 | 2021-07-05 | 2023-05-24 | |
| Multicentric Registry of Patients With Acute Leukemia Infected by COVID-19 Acute Myeloblastic Leukemia, Acute Lymphoblastic Leukemia | Completed | French Innovative Leukemia Organisation | 79 | 2020-09-11 | 2022-07-27 | |
| Study in Plerixafor and Granulocyte-colony Stimulating Factor Patients With Relapse Acute Myeloid Leukemia Plerixafor granulocyte-colony stimulating factor - Acute Myeloid Leukemia | Phase 1 | Terminated | French Innovative Leukemia Organisation | 11 | 2012-01-01 | 2016-03-16 |
| ALFA-0703 Study in Older Patients With Acute Myeloblastic Leukemia (AML) Vesanoid (ATRA), AZACITIDINE (VIDAZA), CYTARABINE - Acute Myeloid Leukemia | Phase 3 | Withdrawn | Acute Leukemia French Association | 2010-04-01 | 2015-12-30 | |
| HCT Versus CT in Elderly AML hematopoietic cell transplantation, Non-Transplant treatment approach for consolidation - Acute Myeloid Leukemia | Phase 3 | Terminated | European Society for Blood and Marrow Transplantation | 126 | 2010-01-01 | 2021-10-14 |
| A Randomized Study of Gemtuzumab Ozogamicin (GO) With Daunorubicine and Cytarabine in Untreated Acute Myeloid Leukemia (AML) Aged of 50-70 Years Old conventional chemotherapy (AraC + Daunorubicin),, Mylotarg associated with conventional chemotherapy (AraC + Daunorubicin), - Acute Myeloid Leukemia | Phase 3 | Completed | Acute Leukemia French Association | 280 | 2007-12-01 | 2013-07-11 |
| Timed-Sequential Induction in CBF-AML Chemotherapy (DAUNORUBICINE-CYTARABINE) - Acute Myeloid Leukemia | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 200 | 2007-07-01 | 2013-12-20 |
| DNR and AraC Combined to Fractionated Mylotarg® in Patients With First Relapse of AML Mylotarg - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Completed | Acute Leukemia French Association | 20 | 2006-06-01 | 2014-07-08 |
| Treatment of Acute Myeloid Leukemia (AML) in Adults 50 to 70 Years, Study of Two Anthracyclines and the Interest of Maintenance Treatment With Interleukin 2 chemotherapy (Aracytine + Daunorubicin) - Acute Myeloid Leukemia | Phase 3 | Completed | Acute Leukemia French Association | 420 | 1999-12-01 | 2009-07-02 |
| A Randomized Study of Post-Remission Therapy in Elderly Patients With Acute Myelogenous Leukemia. Two post-remission strategies, Idarubicin versus daunorubicin - Acute Myeloid Leukemia | Phase 3 | Terminated | Acute Leukemia French Association | 465 | 1999-11-01 | 2008-02-21 |
| Effect of Priming During Induction and Consolidations in Younger Acute Myeloid Leukemia (AML) GM-CSF - Acute Myeloid Leukemia | Phase 3 | Completed | Acute Leukemia French Association | 473 | 1999-03-01 | 2009-04-13 |
| Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Lymphoblastic Leukemia asparaginase, cyclophosphamide, cytarabine - Leukemia, Lymphoma | Phase 3 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 392 | 1995-08-01 | 2013-06-12 |
Leukemia, Myeloid, Acute (18) · Leukemia (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Lymphoma (1) · Recurrence (1)
Cytarabine (5) · Daunorubicin (3) · Azacitidine (2) · Drug Therapy (2) · Mitoxantrone (2) · Asparaginase (1) · CPX-351 (1) · Cyclophosphamide (1) · Dexamethasone (1) · Doxorubicin (1) · Gemtuzumab (1) · Granulocyte-Macrophage Colony-Stimulating Factor (1) · Hydrocortisone (1) · Idarubicin (1) · Leucovorin (1)
France (19) · Belgium (2) · Germany (2) · Netherlands (2) · Australia (1) · Austria (1) · Croatia (1) · Czechia (1) · Italy (1) · Portugal (1) · Slovakia (1) · Switzerland (1) · Turkey (Türkiye) (1)
Castaigne Sylvie, Professor (1) · Denis Fiere, MD (1) · Dietger Niederwieser, Prof (1) · Herve Dombret, M.D. (1)
PMID 20625116, PMID 21459791, PMID 23248249, PMID 23749683, PMID 12239143, PMID 15353542, PMID 15637138, PMID 16939487, PMID 17039234, PMID 17252021, PMID 17407135, PMID 17611565, PMID 18838471, PMID 20378563, PMID 21690555, PMID 23321257, PMID 24616160, PMID 24659740, PMID 26635039, PMID 33858190
2023 (1)